BioCryst Pharmaceuticals | BCRX - Net Income


BioCryst Pharmaceuticals reported $245.84M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Chugai Pharma JPY 115.42B 12.99B Mar/2026
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Incyte USD 303.33M 4.05M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Novavax USD 17.53M 219.91M Dec/2025
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026